Form 4 for WST West Pharmaceutical Services
Accepted 2026-09-10 17:36:54 ET · period of report 2026-09-08 · accession 0000105770-26-000108 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-10 17:36 | 2026-09-08 | WST | Favorite Annette F | SVP, Chief HR Off | M - OptEx | $85.37 | +8,135 | 19.3K | +73% | +$694.5K |
| DM | 2026-09-10 17:36 | 2026-09-08 | WST | Favorite Annette F | SVP, Chief HR Off | S - Sale+OE | $340.81 | -8,135 | 16.8K | -33% | -$2.77M |
| DM | 2026-09-10 17:36 | 2026-09-08 | WST | Favorite Annette F | SVP, Chief HR Off | M - OptEx | $0.00 | -8,135 | 7,524 | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-08 | M | A | 2,817 | $83.47 | 19,661.55 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-08 | S | D | 2,817 | $340.81 | 16,844.55 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price resulting in such weighted average price. |
| 3 | Common | Common Stock | 2026-09-08 | M | A | 2,818 | $83.47 | 19,662.55 | D | — | — | |
| 4 | Common | Common Stock | 2026-09-08 | S | D | 2,818 | $340.81 | 16,844.55 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price resulting in such weighted average price. |
| 5 | Common | Common Stock | 2026-09-08 | M | A | 2,500 | $89.64 | 19,344.55 | D | — | — | |
| 6 | Common | Common Stock | 2026-09-08 | S | D | 2,500 | $340.81 | 16,844.55 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price resulting in such weighted average price. |
| 7 | Derivative | Stock Options (Right to Buy) | 2026-09-08 | M | D | 2,817 | $0.00 | 2,818 | D | $83.47 · — to 2027-02-21 | 2,817 Common Stock | (F2) This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018. |
| 8 | Derivative | Stock Options (Right to Buy) | 2026-09-08 | M | D | 2,818 | $0.00 | 0 | D | $83.47 · — to 2027-02-21 | 2,818 Common Stock | (F2) This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-09-08 | M | D | 2,500 | $0.00 | 7,524 | D | $89.64 · — to 2028-02-20 | 2,500 Common Stock | (F3) This award granted on February 20, 2018 vested in four equal annual installments beginning on February 20, 2019. |